Table 1.

SMIs in HNC clinical trials [137].

Drug	Target	Phase	n	NCT ID	Objective	Results
BAY2416964	AHR	1	78	NCT04069026 [138]	Safety/tumour response study in advanced HNSCC	Safe and demonstrated promising anti-tumour activity in previously treated patients
TPST-1120	PPAR-a	1/1b	38	NCT03829436 [139]	TPST-1120 in combination with Nivolumab vs. TPST-1120 alone for advanced HNSCC	Combination therapy superior to monotherapy with predominately acceptable adverse event profile
AZD9150	STAT3	1b/2	30	NCT02499328 [140]	ASD9150 with Duravalumab vs. Duravalumab alone; in recurrent or metastatic HNSCC refractory to platinum-based chemotherapy	Combination therapy superior to Duravalumab alone with an acceptable adverse event profile
MK-1454	STING	1	157	NCT03010176 [141]	MK-1454 (ulveostinag) with concurrent pembrolizumab vs. MK-1454 alone for advanced stage HNSCC	Concurrent therapy superior to monotherapy alone with an acceptable adverse event profile